Pfizer (United States)-ko ikertzaileekin lankidetzan egindako argitalpenak (29)

2023

  1. Burden of untreated transthyretin amyloid cardiomyopathy on patients and their caregivers by disease severity: results from a multicenter, non-interventional, real-world study

    Frontiers in Cardiovascular Medicine, Vol. 10

  2. Global disparities in patients with multiple myeloma: a rapid evidence assessment

    Blood Cancer Journal, Vol. 13, Núm. 1

2022

  1. Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in Hematology Added Value Framework for Hematologic Malignancies: A Comparative Analysis of Existing Tools

    Value in Health, Vol. 25, Núm. 10, pp. 1760-1767

  2. Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk

    Prostate Cancer and Prostatic Diseases, Vol. 25, Núm. 2, pp. 274-282

  3. Improved Survival with Enzalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer

    Journal of Clinical Oncology, Vol. 37

  4. The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups

    Prostate, Vol. 82, Núm. 13, pp. 1237-1247

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  2. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study

    European Journal of Cancer, Vol. 156, pp. 70-82

  3. The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain

    Mycoses, Vol. 64, Núm. 1, pp. 66-77

2020

  1. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study

    Leukemia, Vol. 34, Núm. 8, pp. 2125-2137

  2. Disease features associated with a low disease impact in patients with psoriatic arthritis: Results of a cross-sectional multicenter study

    Arthritis Research and Therapy, Vol. 22, Núm. 1

  3. The economic burden of metastatic breast cancer in Spain

    European Journal of Hospital Pharmacy , Vol. 27, Núm. 1, pp. 19-24

2019

  1. Very low disease activity, DAPSA remission, and impact of disease in a Spanish population with psoriatic arthritis

    Journal of Rheumatology, Vol. 46, Núm. 7, pp. 710-715

2018

  1. Guidelines on experimental methods to assess mitochondrial dysfunction in cellular models of neurodegenerative diseases

    Cell Death and Differentiation, Vol. 25, Núm. 3, pp. 542-572

2017

  1. Development and validation of a new questionnaire measuring treatment satisfaction in patients with non-valvular atrial fibrillation: SAFUCA®

    Quality of Life Research, Vol. 26, Núm. 3, pp. 767-778

  2. Minimal disease activity and impact of disease in psoriatic arthritis: A Spanish cross-sectional multicenter study

    Arthritis Research and Therapy, Vol. 19, Núm. 1

2016

  1. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

2015

  1. Disability in bipolar i disorder: The 36-item World Health Organization Disability Assessment Schedule 2.0

    Journal of Affective Disorders, Vol. 174, pp. 353-360

2013

  1. The screen for cognitive impairment in psychiatry: Diagnostic-specific standardization in psychiatric ill patients

    BMC Psychiatry, Vol. 13